A meta analysis of the efficacy and safety of moxifloxacin in Chinese patients with multi-drug resistant pulmonary tuberculosisosis

Abstract

This study was performed to evaluate the efficacy and safety of moxifloxacin in treating Chinese patients with multi-drug resistant pulmonary tuberculosisosis (MDR-TB). Medicinal databases and review articles were screened with pre-specified criteria for randomized controlled trials that reported the effects of and adverse reactions to moxifloxacin and other antituberculosisosis drugs in treating Chinese patients with MDR-TB. The quality of included studies was critically evaluated. A total of 948 articles were found and 12 articles finally included. Heterogeneity test: Sputum negative conversion analysis (Q statistic = 9.43, p = 0.58, I-2 = 0%), change of pulmonary tuberculosisosis cavity analysis (Q statistic = 2.93, p = 0.89, I-2 = 0%), focus absorption analysis (Q statistic = 20.13, p = 0.03, I-2 = 50%) and safety analysis (Q statistic = 10.98, p = 0.44, I-2 = 0%). The results of meta-analysis showed that compared with the control group, moxifloxacin was more effective in sputum negative conversion (OR = 3.34, 95% CI: 2.37 to 4.70) and focus absorption (OR = 2.53, 95% CI: 1.55 to 4.12). Moreover, moxifloxacin was safer than control group (OR = 0.73, 95% CI: 0.55 to 0.96). Funnel-plot displayed some unsymmetrical figures, indicating there were publication biases in each analysis. The evidence currently available shows that the moxifloxacin treatment on Chinese patients with MDR-TB is useful for the sputum negative conversion and focus absorption.